MRP and MDR1 gene expression in primary breast carcinomas.
To evaluate the clinically important mechanisms of drug resistance in breast cancer, the expression of the MRP gene and the corresponding one for the MDR1 gene were determined in primary breast carcinoma specimens by both reverse transcription-PCR (n = 134) and immunohistochemistry (n = 63). Expression of MRP RNA was observed in all breast cancer specimens. MDR1 RNA was detected in 80 (60%) of the carcinomas. Staining with monoclonal antibodies QCRL-1 and QCRL-3, which both recognize MRP, was strong in 15 (24%) and weak in the remaining 48 specimens (76%). Staining with C219, which recognizes P-glycoprotein, was strong in 6 (9%), weak in 30 (48%), and negative in 27 (43%) of the samples. Strong MRP staining was more frequent in T3 and T4 tumors than in T1 and T2 tumors and in the primary tumors of patients with distant metastases but was independent of age, menopausal status, histology, histological grade, estrogen receptor, progesterone receptor, and lymph node involvement. No correlation between MRP staining and expression of MDR1 RNA or P-glycoprotein was observed. Thus, these results indicate expression of both the MRP gene and the MDR1 gene in primary breast carcinomas and suggest that clinical drug resistance in breast cancer is most likely multifactorial.